🎮 $U | Unity Q2 2025 Earnings Summary 🔹 Revenue: $440.9M (expected $426.7M) ✅ → However, -2% YoY contraction 🔹 Adj. EPS: $0.18 (expected -$0.28) ✅ 📊 Q2 Segment Details: 🔸 Create Solutions: $154M (+2% YoY) 🔸 Grow Solutions: $287M (-4% YoY) 🔸 Unity Ad Network: +15% QoQ → 49% of the Grow segment 📈 Q3 Guidance: 🔹 Revenue: $440M–$450M (expected $445.1M) ➖ 🔹 Adj. EBITDA: $90M–$95M 🔹 "Grow" segment: Mid-single-digit quarterly growth expected 🔹 "Create" segment: Slight contraction expected 💰 Operational Data: 🔹 Adj. EBITDA: $90M (21% margin) 🔹 Free Cash Flow: $127M (previously $80M) 🔹 Net Operating Cash: $133M (previously $88M) 🔹 Cash & Cash Equivalents: $1.70B ($1.53B in December 2024) 🗣️ CEO Matt Bromberg: This quarter is a turning point for Unity. Our Unity Vector strategy is reshaping our growth potential. We surpassed the upper bounds in both revenue and EBITDA. 📌 Comment: Unity delivered a strong positive surprise in EPS and EBITDA, but annual revenue remains negative. The growth side is declining, but the ad network's recovery is positive. The create side is experiencing stable but limited growth. There is a significant improvement in cash flow, and the balance sheet is becoming more resilient. 🔸 The "Unity Vector" strategy may herald a transformation. 🔸 Limited growth in the short term, with a more aggressive recovery possible in the medium term. 🔸 Margins are strong, and operational efficiency is improving. Unity is still in transition, but signs of a bottoming out are becoming clear. #Unity #U #Earnings #GameDev #AdTech #Q22025 #TechStocks #TradersPub #Investment #BalanceSheetAnalysis

Oscar ($OSCR), like its competitors, has been negatively impacted by the rise in the US morbidity rate. Morbidity refers to the average health deterioration in the US population. While the exact cause is unknown, Americans are now less healthy. The impact is reflected in the "Medical loss ratio" line on the income statement. This means the company is now paying more premiums back to policyholders as claims. I thought morbidity could be a problem, but Oscar could manage it with artificial intelligence applications. It seems I was wrong, at least for now. I was predicting OSCR could better select and price patients with AI, but that's been a lie for now. 📈 Oscar Health 2025 Q2 Results Announced! 📉 Oscar Health announced its Q2 2025 financial results. While revenue and EPS fell short of expectations, the company maintained its year-end revenue guidance. Here are the details: 🔹 Revenue: 2.86 Billion (Expected 2.92 Billion) 🔴 🔹 Earnings per Share (EPS): -0.89 (Expected -0.84) 🔴 🔹 Memberships: 2.03 Million (+29% YoY increase) Annual revenue guidance remained unchanged at 12.0 Billion - 12.2 Billion. The company stated that it experienced a loss in the quarter due to increased risk adjustment costs in the insurance market. CEO Mark Bertolini: "We believe the individual market has long-term potential and that the future is in healthcare." #OscarHealth #OSCR #Finance #StockMarket #Technology #Healthcare #Investment #Economy

📉 German Factory Orders Drop Unexpectedly in June 🔹 June 2025: -1.0% (Expected: +1.0%) ❌ 🔹 May (revised): -0.8% 🔹 Second consecutive month of decline! 📉 Main reason: – Sharp decline of -23.1% in aircraft, ship, train, and military vehicle orders ✈️🚢🚆 – Demand also weakened for automotive and metal products 🚗🔧 🔌 Electrical equipment orders increased ✅ 📊 3-month average (Q2): +3.1% – Orders brought forward ahead of global tariff hikes and the trade recovery in the Eurozone supported 🌍📦 #Germany #DAX #EWG #Economy #IndustrialOrders #EURUSD #RecessionRisk

According to analyst Ming-Chi Kuo, US President Donald Trump's alleged $300 billion investment in Taiwan Semiconductor Manufacturing Company (TSMC) is paving the way for upcoming semiconductor tariffs. 📈 According to Kuo, this claim is part of Trump's negotiating tactic. Noting that the officially announced investment is $165 billion, Kuo believes Trump aims to start negotiations with this high figure and then offer a discount. #TSMC #TSM #DonaldTrump #Semiconductor #US #Economy #TariffWar #Investment

If you see ethical issues in a company's governance, you'll stay away from it. SMCI, initially shaken by accounting scandals, yesterday lowered its 2026 revenue forecast from $40 billion to $33 billion. SMCI had presented such an ambitious target to recover from the accounting scandal. Today, we understand it was a fabrication. It's a great stock to trade, but it's definitely not an investment stock.

I liked yesterday's pullback, as my expectations for AMD are focused on the second half of the year. I'll be able to buy some more shares. Because Chinese export restrictions haven't been clarified, they've been forced to write off their inventory as a loss, hurting their profitability. The effect is temporary. The game will change in the second half.

Novo Nordisk's Q2 earnings report fell short of expectations, but sales of its weight-loss drug Wegovy were impressive! 🟢 However, due to competition and slowing GLP-1 growth, the company lowered its full-year guidance and is considering a CEO change. 📉 #NovoNordisk #NVO #StockMarket #Finance #Wegovy #Ozempic #EarningsReport

#GDPNow GDPNow has raised its Q3 growth forecast from +2.1% to +2.5%. The growth rate of the US economy, or real GDP (GDP) growth rate, is one of the most important indicators of economic activity. However, official growth figures are often released with a lag. That's where the GDPNow model, developed by the Atlanta Fed, comes in! 🏦✨ GDPNow uses available economic data for a given period to generate a "nowcast" economic growth forecast before the official release.

A New Era in the US-China Truce 🔹 Trump: "Trade deal is very close" 🔹 A package focused on mutual tax reductions and rare earths 🟡 A sign of short-term easing in global risk appetite.

Trump's New Tariff Move: 250% Tax on Medicines Possible 🔹 Tariffs planned for the chip and pharmaceutical sectors 🔹 Taxes on medicine imports could be raised from 150% to 250% 🟣 Pressure on global supply chains could increase.

📉 Unfortunately, a lackluster earnings report for AMD. I was afraid of weak EPS, and it came true. At least there are positive signals on the forward guidance side. However, when expectations are set high, high price volatility is inevitable. If we hold above $170, perhaps even close the week above this level, we will have survived with minimal damage. The market loves to exaggerate. Conversely, if a correction is possible, a dip to $140-$150 could be a buying opportunity for those looking to add to their portfolio. 📢 Here are my key points: • Q3 guidance does not include the MI308 revenues planned for sale to China. The sale is still awaiting approval. However, there is a large amount of equipment in stock, ready for immediate shipment. • We still haven't seen the expected AI boom. Lisa Su points to the MI350 ramp-up for this. The market and investors now want to see results. The second half of 2025 is critical.